Skip to main content

Security report for orchard-tx.com

Orchard Therapeutics plc · Healthcare · United Kingdom

Medium risk. 7 critical or high findings in Security headers, GDPR outside view and 2 other checks.

Security score

62/100

Risk levelMedium

0–100, higher is better. How it is calculated

Orchard Therapeutics plc is a biotechnology company specializing in hematopoietic stem cell gene therapies aimed at treating severe genetic diseases. The company positions itself as a pioneer in gene therapy with a focus on transforming patient lives through innovative medical solutions. Their website targets patients, families, healthcare professionals, and investors, providing educational resources, corporate information, and investor relations content. The business model centers on research, development, and commercialization of gene therapies within the healthcare sector, primarily in the UK and international markets. Technically, the website is built on WordPress with modern SEO and analytics tools such as Yoast SEO, Google Analytics, and Google Tag Manager. The site is mobile-optimized and demonstrates good performance and accessibility standards, though some improvements in accessibility and security headers could be made. The presence of privacy and cookie policies with consent mechanisms indicates a commitment to privacy compliance. From a security perspective, the site enforces HTTPS and avoids exposing sensitive data. However, the lack of visible security headers and absence of explicit incident response contacts or vulnerability disclosure mechanisms suggest areas for enhancement. The missing WHOIS data for the domain raises concerns about domain legitimacy, though the website content and external references support the company's authenticity. Overall, the website is professional, informative, and trustworthy, but improvements in domain registration transparency and security posture would strengthen its credibility and resilience against threats.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

7 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching orchard-tx.com

This scan found 26 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
52
Security headers
15
Email security
75
DNS health
60
Network security
100
GDPR outside view
68
Average
62

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Orchard Therapeutics operates in the specialized gene therapy market, focusing on rare and severe genetic diseases. Their competitive advantage lies in their proprietary HSC gene therapy platform and decades of research backing. The company targets multiple customer segments including patients, families, healthcare professionals, and investors. Revenue streams likely include therapy development partnerships, licensing, and eventual commercialization. The company maintains a strong partnership ecosystem evidenced by investor relations and multiple regional domains. Growth indicators include active content updates, social media engagement, and compliance with privacy regulations. Strategic observations suggest a focus on expanding gene therapy applications and maintaining regulatory compliance to support market expansion.

Security posture

The website demonstrates a moderate to good security maturity level with enforced HTTPS and cookie consent mechanisms. No critical vulnerabilities or exposed sensitive data were detected. However, the absence of key security headers such as Content-Security-Policy and Strict-Transport-Security reduces the overall security posture. The lack of a published security.txt or vulnerability disclosure policy limits transparency and incident response readiness. No explicit security contact emails were found, which could hinder timely reporting of security incidents. Compliance with GDPR is indicated by privacy and cookie policies, but further enhancements in security culture and incident response are recommended.

Recommendations

  1. Implement comprehensive security headers including Content-Security-Policy, X-Content-Type-Options, and Strict-Transport-Security to enhance protection against common web attacks.
  2. Publish a security.txt file and establish a clear vulnerability disclosure policy to improve transparency and facilitate responsible reporting.
  3. Add explicit incident response contact information such as security@ or abuse@ email addresses to enable efficient communication during security events.
  4. Verify and update domain WHOIS information to ensure transparency and improve domain legitimacy trust signals.
  5. Conduct regular security audits and penetration testing to identify and remediate potential vulnerabilities proactively.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Orchard Therapeutics plc
Description
Orchard Therapeutics is a biotechnology company focused on developing hematopoietic stem cell (HSC) gene therapies for severe genetic diseases. They build on decades of research to apply their gene therapy platform to areas of significant medical need, aiming to transform lives of patients with severe genetic diseases.
Key services
HSC gene therapy development, Patient and family support information, Healthcare professional resources
Content quality
good
Branding
consistent

Technology

Stack
WordPress, Yoast SEO plugin, Google Analytics, Google Tag Manager, jQuery, Vimeo Player API
Platforms
WordPress CMS
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • No exposed sensitive data in HTML
  • Cookie consent banner implemented

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professionally presented and relevant to gene therapy healthcare sector.
  3. No direct company contact emails or phone numbers found in the HTML; contact is via form.
  4. Strong presence of privacy and cookie policies with consent mechanism.
  5. WHOIS data unavailable, which reduces trustworthiness from a domain registration perspective.
  6. Use of modern web technologies and SEO best practices.
  7. Social media presence on Twitter and LinkedIn is linked.
  8. No security.txt or explicit vulnerability disclosure found.
  9. No explicit incident response or security contact information found.
Technical notes

Notes

The website is built on a WordPress CMS platform using modern web technologies including Yoast SEO for search optimization, Google Analytics and Tag Manager for user tracking, and jQuery for client-side scripting. The site loads multiple external scripts asynchronously to optimize performance. Mobile responsiveness and SEO optimization are well implemented. However, the site lacks advanced security headers and explicit hosting provider information. Performance is moderate with room for improvement in accessibility features. The technical infrastructure supports the business goals but could benefit from modernization in security and performance monitoring.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with orchard-tx.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review orchard-tx.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.